EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead

Chase J Morgan, Haley Atkins, Alan J Wolfe, Linda Brubaker, Saima Aslam, Catherine Putonti, Michael B Doud, Lindsey A Burnett iD

International Urogynecology Journal · 2025

DOI: 10.1007/s00192-025-06136-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Urogynecology Journal, 2025. Verfasst von Chase J Morgan und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, Division of Molecular Biology, University of California San Diego, La Jolla, CA, 92093, USA. Hauptthemen laut MEDLINE: Urinary Tract Infections, Phage Therapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NICHD NIH HHS, International Urogynecological Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Hypothesis Urinary tract infection (UTI) treatment is a growing public health concern owing to increasing antimicrobial resistance. Phage therapy, an alternative or adjunctive treatment to antibiotics, has the potential to address this challenge. However, clinical use of phage therapy is hindered by knowledge gaps and inconsistent reporting. The objective was to review the current state of phage therapy for UTIs and highlight research priorities that can optimize phage clinical efficacy.

Methods

Current literature on UTI phage therapy was examined, focusing on the lack of standardized phage susceptibility testing, phage characterization, and microbiological assessments during and after treatment.

Results

Critical areas requiring further investigation include appropriate phage dosing, optimal routes of administration, and the dynamics of phage–host and phage–patient interactions. The influence of the urinary microbiome, including endogenous phages, on treatment outcomes also needs to be better understood. Suggested data collection and reporting standards should be developed and implemented to improve clinical impact of studies examining phage therapy for UTI. Randomized clinical trials are needed to establish efficacy and determine the best practices for clinical use.

Conclusion

Phage therapy is a promising alternative to antibiotics for managing UTIs, especially in the face of rising antimicrobial resistance. To fully realize its potential, however, future research must focus on standardized protocols, dosing strategies, and the role of the urinary microbiome, with an emphasis on rigorously conducted clinical trials. These steps are essential for integrating phage therapy into mainstream UTI treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsPhage TherapyHumansMicrobial Sensitivity TestsUrinary TractMicrobiotaBacteriophages

Stichwörter der Autor:innen

Phage therapyUrinary phageUrinary tract infectionUrinary virome

Autor:innen und Institutionen

  • School of Biological Sciences, Division of Molecular Biology, University of California San Diego, La Jolla, CA, 92093, USA.
  • Bioinformatics Program, Loyola University Chicago, Chicago, IL, USA.
  • Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, USA.
  • Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics, Gynecology, and Reproductive Sciences, UC San Diego, 9300 Campus Point Dr, Mail Code 7433, La Jolla, CA, 92037, USA.
  • Center for Innovative Phage Applications and Therapeutics, La Jolla, CA, USA.
  • Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, 9500 Gilman Dr, Mail Code 0116, La Jolla, CA, USA.

ORCID-Profile: Lindsey A Burnett

Förderung

  • NIAID NIH HHS
  • NICHD NIH HHS
  • International Urogynecological Association
  • Reproductive Scientist Development Program
  • ACTRI Pilot Project

Zitieren

APA

Morgan, C. J., Atkins, H., Wolfe, A. J., Brubaker, L., Aslam, S., Putonti, C., Doud, M. B., & Burnett, L. A. (2025). Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead. International Urogynecology Journal. https://doi.org/10.1007/s00192-025-06136-8

Vancouver

Morgan CJ, Atkins H, Wolfe AJ, Brubaker L, Aslam S, Putonti C, et al. Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead. International Urogynecology Journal. 2025. doi:10.1007/s00192-025-06136-8

BibTeX
@article{Morgan2025,
  author = {Morgan, Chase J and Atkins, Haley and Wolfe, Alan J and Brubaker, Linda and Aslam, Saima and Putonti, Catherine and Doud, Michael B and Burnett, Lindsey A},
  title = {Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead},
  journal = {International Urogynecology Journal},
  year = {2025},
  doi = {10.1007/s00192-025-06136-8}
}
Kostenlos starten →